Memantine, Donepezil, or Combination Therapy—What is the best therapy for Alzheimer’s Disease? A Network Meta‐Analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Memantine, Donepezil, or Combination Therapy—What is the best therapy for Alzheimer’s Disease? A Network Meta‐Analysis
Authors
Keywords
-
Journal
Brain and Behavior
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-09-21
DOI
10.1002/brb3.1831
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Alzheimer’s disease: targeting the glutamatergic system
- (2020) Myra E. Conway BIOGERONTOLOGY
- An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease
- (2020) Andrea Haake et al. Expert Opinion On Drug Safety
- Neuroinflammation and Neurogenesis in Alzheimer’s Disease and Potential Therapeutic Approaches
- (2020) Pi-Shan Sung et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Does the neuropsychiatric inventory predict progression from mild cognitive impairment to dementia? A systematic review and meta-analysis
- (2019) Sabela C. Mallo et al. AGEING RESEARCH REVIEWS
- The Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review
- (2018) Jacqueline K. Kueper et al. JOURNAL OF ALZHEIMERS DISEASE
- An evaluation of memantine ER + donepezil for the treatment of Alzheimer’s disease
- (2018) Amanda Calhoun et al. EXPERT OPINION ON PHARMACOTHERAPY
- The Possibility of an Infectious Etiology of Alzheimer Disease
- (2018) Ghulam M. Ashraf et al. MOLECULAR NEUROBIOLOGY
- Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis
- (2017) Ruey Chen et al. PLoS One
- Anti-Inflammatory Action of Donepezil Ameliorates Tau Pathology, Synaptic Loss, and Neurodegeneration in a Tauopathy Mouse Model
- (2017) Yasumasa Yoshiyama et al. JOURNAL OF ALZHEIMERS DISEASE
- Uncertainty in Treatment Rankings: Reanalysis of Network Meta-analyses of Randomized Trials
- (2016) Ludovic Trinquart et al. ANNALS OF INTERNAL MEDICINE
- Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)
- (2016) Martin Knapp et al. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
- Memantine in Patients with Moderate to Severe Alzheimer's Disease: Meta-Analyses Using Realistic Definitions of Response
- (2013) David Wilkinson et al. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
- Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease
- (2012) Serge Gauthier et al. Alzheimers & Dementia
- Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- Neuropsychiatric symptoms in Alzheimer’s disease
- (2011) Constantine G. Lyketsos et al. Alzheimers & Dementia
- The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Marilyn S. Albert et al. Alzheimers & Dementia
- The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease
- (2010) Jaclyn Cappell et al. CNS DRUGS
- The neuropathology of probable Alzheimer disease and mild cognitive impairment
- (2009) Julie A. Schneider et al. ANNALS OF NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started